Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited has announced the redemption of all remaining convertible notes held by Obsidian Global GP, LLC, which were funded from existing cash reserves. This redemption eliminates the potential dilution from the conversion of these notes, as no convertible notes remain outstanding. The company aims to simplify its capital structure and strengthen its financial position ahead of an important clinical trial readout. Future drawdowns under the convertible note facility will require shareholder approval and will not occur until at least April of the following year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Redemption of all remaining Obsidian convertible notes Highlights: ? Neurizon has redeemed the remaining 750,000 convertible notes held by Obsidian Global GP, LLC (“Obsidian”) for US$915,750 (~A$1.31m), funded from existing cash...
Neurizon Therapeutics Limited on 6ix
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics